What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cancer
Stephen I. Rennard focuses on COPD, Internal medicine, Placebo, Anesthesia and Pathology.
His COPD study incorporates themes from Respiratory disease, Immunology, Intensive care medicine, Physical therapy and Severity of illness.
His studies in Internal medicine integrate themes in fields like Gastroenterology and Surgery.
The study incorporates disciplines such as Tolerability, Adverse effect, Randomized controlled trial, Abstinence and Cilomilast in addition to Placebo.
His Anesthesia study combines topics in areas such as Bronchodilator, Ipratropium, Clinical trial and Smoking cessation.
The various areas that Stephen I. Rennard examines in his Pathology study include Cell culture, Chronic bronchitis, Bronchoalveolar lavage, Lung and Respiratory system.
His most cited work include:
- A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation (1388 citations)
- Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial (1122 citations)
- Changes in forced expiratory volume in 1 second over time in copd (658 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are COPD, Internal medicine, Immunology, Lung and Fibroblast.
His COPD research is multidisciplinary, incorporating perspectives in Pulmonary disease, Anesthesia, Physical therapy and Intensive care medicine.
The Anesthesia study combines topics in areas such as Metered-dose inhaler and Bronchodilator.
His Internal medicine research includes themes of Placebo, Endocrinology, Smoking cessation and Cardiology.
He has included themes like Abstinence and Nicotine in his Smoking cessation study.
His work deals with themes such as Cancer research and Pathology, which intersect with Lung.
He most often published in these fields:
- COPD (36.69%)
- Internal medicine (32.25%)
- Immunology (13.99%)
What were the highlights of his more recent work (between 2013-2021)?
- COPD (36.69%)
- Internal medicine (32.25%)
- Physical therapy (10.58%)
In recent papers he was focusing on the following fields of study:
Stephen I. Rennard mostly deals with COPD, Internal medicine, Physical therapy, Pulmonary disease and Cohort.
Stephen I. Rennard combines subjects such as Exacerbation, Intensive care medicine, Placebo, Lung and Disease with his study of COPD.
In his research, Fixed-dose combination, Chronic bronchitis, Metered-dose inhaler and Randomized controlled trial is intimately related to Anesthesia, which falls under the overarching field of Placebo.
His Lung research incorporates elements of Lung cancer, Pathogenesis and Pathology.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Cardiology.
His Physical therapy research is multidisciplinary, incorporating elements of Biomarker, Observational study, Hazard ratio and Surrogate endpoint.
Between 2013 and 2021, his most popular works were:
- CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease (133 citations)
- Effect of Varenicline on Smoking Cessation Through Smoking Reduction: A Randomized Clinical Trial (113 citations)
- Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. (112 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cancer
COPD, Internal medicine, Physical therapy, Pulmonary disease and Placebo are his primary areas of study.
His research integrates issues of Quality of life, Intensive care medicine, Biomarker, Bronchodilator and Cohort in his study of COPD.
His Internal medicine study incorporates themes from Gastroenterology, Genetic variation and Cardiology.
His work deals with themes such as Regression analysis, Disease and Hazard ratio, which intersect with Physical therapy.
His Placebo research is multidisciplinary, relying on both Dry-powder inhaler, Anesthesia, Tolerability, Randomized controlled trial and Formoterol.
Stephen I. Rennard works mostly in the field of Anesthesia, limiting it down to concerns involving Chronic bronchitis and, occasionally, Gene expression profiling and Gene expression.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
